Dr. Lal Path Labs Ltd. — Investor Meet, 01-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs reported 10.5% revenue growth for Q4 and FY25 at Rs. 603 Cr and Rs. 2,461 Cr. EBITDA rose 16.9% QoQ to Rs. 169 Cr (28.1% margin), and PAT jumped 81.4% to Rs. 156 Cr, helped by a Rs. 40.8 Cr one-time tax gain. Sample volumes increased 9.5%, patient volumes 3.8%, with SwasthFit tests up 22%. The network grew with 18 new labs and ~1,000 centers, focusing on Tier-3/4 towns and digital initiatives. Management aims for 11-12% revenue growth and ~27% margins in FY26, with cautious pricing and ongoing expansion investments.